|
||||||
| Home |
| Find a Clinical Trial |
| Clinical Trial FAQs |
| About Informed Consent |
| Clinical Trials Glossary |
| Medical Research Areas |
| Clinical Trial Resources |
|
 |
Sign up and receive information about Novartis clinical trials in your health-related areas of interest. For U.S. residents only. | |
|
|
 |
|
|
|
|||
|
Novartis Clinical
Trials provides information about research studies recruiting
within the U.S. Visit ClinicalTrials.gov, a registry of federally and privately supported clinical trial for more information regarding clinical trials outside of the U.S. |
|
|
Find a Clinical Trial
Breast Cancer
Among cancer deaths in US women, those due to breast cancer are second only to those of lung cancer. Age is a factor - 80% of breast cancers occur in women over 50. In younger women, genetic factors may play a role. Because growth of breast tissue is highly sensitive to estrogens, the more a woman is exposed to estrogen over her lifetime, the higher the risk for breast cancer.
Novartis is seeking people to participate in a clinical trial(s) testing the safety and effectiveness of Novartis products. Novartis recommends that you consult your doctor before participating in a clinical trial. For more information about clinical trial participation, click here. Also, for additional information about how Novartis helps to protect the privacy of the personal information that you provide to us, please see the Novartis Privacy Policy. Please review the details of the clinical trial(s) listed below and click on the one that you feel best suits your (or the participant's) condition.
Breast Cancer (Bone Metastases) Study - E2352
A randomized, double-blind, stratified, multicenter trial to test the continued efficacy and safety (every 4 weeks vs. every 12 weeks) of an existing therapy in people with documented bone metastases from breast cancer.
Trial phase: Phase 3 Participation Duration: Study will require 15 visits to the study center over a period of 13 months. Visits may last approximately 2 hours. Protocol Number: CZOL446E2352 Metastatic Breast Cancer Trial - Y2301
The purpose of this phase III study is to compare efficacy and safety of a Novartis investigational drug along with an additional therapy in treating postmenopausal women with estrogen receptor positive (ER+) locally advanced or metastatic breast cancer refractory to nonsteroidal aromatase inhibitors (NAI). An "investigational drug" is a drug that is being clinically tested and is not approved for sale or use in the United States by the Food and Drug Administration (FDA), for the indication in which it is being studied.
Trial phase: Phase 3 Participation Duration: The planned duration of this trial will be 24 weeks, with post assessment visits every 6 weeks until trial completion. Protocol Number: CRAD001Y2301
HER2 Positive Breast Cancer Trial - J2301
The purpose of this randomized, phase III, double-blind, placebo-controlled, multicenter study is to evaluate the safety and efficacy of combining a Novartis investigational drug with standard chemotherapy medicines in women with HER2 positive (HER2+) locally advanced or metastatic breast cancer. An "investigational drug" is a drug that is being clinically tested and is not approved for sale or use in the United States by the Food and Drug Administration (FDA), for the indication in which it is being studied.
Trial phase: Phase 3 Participation Duration: Participants will be asked to visit a study center 4 times a month for a period of 6 months or until the disease progresses Protocol Number: CRAD001J2301 HER2 Advanced or Metastatic Breast Cancer Trial - W2301
The purpose of this randomized, phase III, double-blind, placebo-controlled multicenter study is to evaluate if adding a Novartis investigational drug to an existing combination therapy offers a more positive “progression-free” result in pretreated women with HER2/Neu Over-Expressing Locally Advanced or Metastatic Breast Cancer. An "investigational drug" is a drug that is being clinically tested and is not approved for sale or use in the United States by the Food and Drug Administration (FDA), for the indication in which it is being studied.
Trial phase: Phase 3 Participation Duration: Participants will be asked to visit the study center Once a week for a period of 6-9 months or until the disease has progressed. Protocol Number: CRAD001W2301 |